Sarepta Therapeutics: Time To Change My Game Plan After Q4 Earnings

Sarepta Therapeutics: Time To Change My Game Plan After Q4 Earnings By Biologics U.S. IPO Weekly Recap: February Closes Out With One Micro-Cap As IPO Calendar Gets A Boost By Renaissance Capital IPO Research SQM: The Low-Cost Producer And Double-Digit Dividend Yield By George Atuan, CFA FEATURED: Go Premium for $4.95 for your first 30 days Get the bull and bear perspective on 1000s of stocks with Seeking Alpha's diverse pool of contributors and community debate. Join Premium for only $4.95 for your first 30 days. Go Premium now » Long Ideas T. Rowe Price Group: Reasonable Valuation And Strong Balance Sheet By UFD Capital Pure Storage: Buy The Dip And Focus On Cash Flow By Gary Alexander Lincoln National: Why I Am Long, Buying More, And Keeping What I Have By Wolf Report Perion Network: Still Very Discounted By Felix Fung Veeva Q4 Earnings: Another Solid Quarter In The Books By Kennan Mell More Long Ideas » Quick Picks & Lists Danaher: Compounder Starts To Look Attractive By The Value Investor Casey's General Stores: Time To Refuel On M&A By The Value Investor Housing Market 2023 - Some Growth Picks For The Upswing In Demand By Damon Judd MDA Breakout Stocks Week 10 - March 2023: High-Frequency Gainers To Give You An Edge By JD Henning More Quick Picks & Lists » Download the Seeking Alpha App! Like Stock Ideas? Try our other newsletters as well. This email was sent to you because you signed up to receive Stock Ideas. If you do not want to receive Stock Ideas emails, click here to unsubscribe. Sent by Seeking Alpha, 234 5th Ave, 5th floor, New York, NY 10001